文献速递关节外科创伤骨科

围手术期地塞米松与全关节置换术后肺栓塞和深静脉血栓风险降低相关:对70,000例高危患者的分析

Perioperative Dexamethasone is Associated With a Decreased Risk of Pulmonary Embolism and Deep Vein Thrombosis Following Total Joint Arthroplasty: An Analysis of 70,000 High-Risk Patients.
PubMed 文献 · J Arthroplasty · 2024-05-10

该研究利用商业健康数据库纳入2015至2021年接受初次择期全关节置换术且有静脉血栓栓塞症病史的70,147例患者,比较围手术期静脉给予地塞米松组与未给予组术后90天并发症风险。地塞米松组肺栓塞和深静脉血栓发生率均较低,校正后风险亦降低,而手术部位感染、假体周围感染或脓毒症风险无差异。

要点

  • 有静脉血栓栓塞症病史的全关节置换患者中,围手术期静脉地塞米松组肺栓塞发生率为1.37%,未给予组为1.75%。
  • 地塞米松组深静脉血栓发生率为2.37%,未给予组为3.01%。
  • 校正后地塞米松组肺栓塞风险降低(校正比值比0.78),深静脉血栓风险降低(校正比值比0.84)。

核心结论

  • 在有静脉血栓栓塞症病史并接受全关节置换术的患者中,给予地塞米松与肺栓塞和深静脉血栓风险降低相关。
  • 这些数据需要进一步研究围手术期地塞米松给药对接受全关节置换术高危患者的术后获益。

研究设计与样本

  • 利用商业健康数据库识别2015至2021年接受初次择期全关节置换术且有静脉血栓栓塞症病史的患者。
  • 根据索引全关节置换术当天是否接受围手术期静脉地塞米松分为地塞米松组和未给予地塞米松组,比较术后90天并发症、再入院和院内死亡风险。
  • 证据等级为III级。

主要发现

  • 共70,147例有静脉血栓栓塞症病史的患者接受全关节置换术,其中40,607例(57.89%)接受地塞米松,29,540例(42.11%)未接受。
  • 地塞米松组患者较未给予组更年轻(67±9.8岁 vs 68±9.9岁,P<.001),住院时间更短(1.8±1.6天 vs 2.2±1.8天,P<.001)。
  • 地塞米松组肺栓塞发生率低于未给予组(1.37% vs 1.75%,P<.001),深静脉血栓发生率亦低于未给予组(2.37% vs 3.01%,P<.001)。
  • 地塞米松组肺栓塞风险低于未给予组(校正比值比0.78,95%置信区间0.66至0.93,P=.006),深静脉血栓风险亦低于未给予组(校正比值比0.84,95%置信区间0.74至0.95,P=.006)。
  • 地塞米松组与未给予组在手术部位感染、假体周围感染或脓毒症的比值上无差异(P>.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些数据需要进一步研究围手术期地塞米松给药对接受全关节置换术高危患者的术后获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dexamethasone (DEX) has demonstrated promise with respect to decreasing postoperative thromboembolic complications following total joint arthroplasty (TJA). Therefore, the aim of this study was to investigate the effects of perioperative intravenous DEX on rates of pulmonary embolism (PE) and deep vein thrombosis (DVT) after primary TJA in patients who have a history of venous thromboembolism (VTE). METHODS: Patients who have a history of VTE who underwent primary elective TJA from 2015 to 2021 were identified using a commercial health care database. Patients were divided based on receipt of perioperative intravenous DEX [DEX(+) versus DEX(-)] on the day of index TJA. Patient demographics and hospital factors were collected. The 90-day risk of postoperative complications, readmission, and in-hospital mortality were compared. RESULTS: Overall, 70,147 patients who had a history of VTE underwent TJA, of which 40,607 (57.89%) received DEX and 29,540 (42.11%) did not. The DEX(+) patients were younger (67 ± 9.8 versus 68 ± 9.9 years, P < .001) and had a significantly shorter length of stay compared to the DEX(-) patients (1.8 ± 1.6 versus 2.2 ± 1.8 days, P < .001). The DEX(+) patients demonstrated lower rates of PE (1.37 versus 1.75%, P < .001) and DVT (2.37 versus 3.01%, P < .001) compared to DEX(-) patients. The DEX(+) patients experienced a lower risk of PE (adjusted odds ratio: 0.78, 95% confidence interval: 0.66 to 0.93, P = .006) and DVT (adjusted odds ratio: 0.84, 95% confidence interval: 0.74 to 0.95, P = .006) compared to DEX(-) patients. The DEX(+) patients demonstrated no differences in the odds of surgical site infection, periprosthetic joint infection, or sepsis compared to the DEX(-) patients (P > .05). CONCLUSIONS: The administration of DEX was associated with a decreased risk of PE and DVT in patients who have a history of VTE who underwent TJA. These data warrant further study investigating the postoperative benefits of perioperative DEX administration for high-risk patients undergoing TJA. LEVEL OF EVIDENCE: Level III.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Gettleman BS, Liu KC, Yoshida B, et al. Perioperative Dexamethasone is Associated With a Decreased Risk of Pulmonary Embolism and Deep Vein Thrombosis Following Total Joint Arthroplasty: An Analysis of 70,000 High-Risk Patients. J Arthroplasty. 2024. PMID: 38735549. doi:10.1016/j.arth.2024.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。